FDA approves Sage’s postpartum depression drug 

Postpartum depression is the most common complication of childbirth. Yesterday the FDA approved brexanalone, the first drug to treat the condition, which affects 400,000 American women every year but often goes untreated because new mothers can be stigmatized about reporting symptoms.

It’s also the first-ever drug developed by and approved from Sage Therapeutics. But as STAT’s Adam Feuerstein notes, there are challenges that might limit use of the drug, called Zulresso: It's administered via an intravenous infusion over 60 hours and women must be treated at an inpatient facility or hospital where they can be monitored.

Read more.